FDA Grants Orphan Drug Designation to PVSRIPO for Treatment of Advanced Melanoma

The novel viral immunotherapy PVSRIPO is designed to stimulate a patient’s innate and adaptive immune system to promote an antitumor response and establish long-term immunologic memory to help keep their cancer at bay.

The FDA has granted orphan drug designation to the novel viral immunotherapy PVSRIPO for the treatment of patients with advanced stage IIB through IV melanoma, according to Istari Oncology, the developer of the agent.¹

PVSRIPO is designed to stimulate a patient’s innate and adaptive immune system to promote an anti-tumor response and establish long-term immunologic memory to help prevent the cancer’s return.

Istari is currently recruiting for the open-label, randomized, phase 2 LUMINOS-102 (NCT04577807) trial of PVSRIPO in patients with PD-1 refractory melanoma. The study plans to characterize the safety, tolerability, and initial efficacy of PVSRIPO intratumoral injection alone and in combination with a PD-1 inhibitor.

The company plans to dose the first patient this quarter.

“We are happy to kick off the new year with the announcement that our request for an orphan drug designation has been granted to PVSRIPO for the treatment of advanced melanoma,” Matt Stober, president and chief executive officer at Istari Oncology, said in a press release. “This is just one of many milestones to come in 2021 as we continue to drive the clinical development of PVSRIPO across multiple indications.”

LUMINOS-102 will follow the successful phase 1 monotherapy study (NCT03712358) of PVSRIPO in anti–-PD-1 refractory advanced melanoma, results of which were previously presented at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting.²

To Read the Complete Article at Cancer Network, Click Here

Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use, reference to, or reliance on any information contained within the article. Content available through the site may contain links and information to other websites. Links from BioPharma Global to third-party sites do not constitute an endorsement by BioPharma Global of the mentioned parties.

BioPharma Global is a mission-driven corporation, operating like a not-for-profit, dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with a high unmet medical need. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.

Stock image by @tatsianama from Depositphotos